Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
The U.S. Food and Drug Administration (FDA) issued a diabetes guidance in 2008 mandating that all new antidiabetes drugs rule out excess cardiovascular (CV) risk, defined as an upper bound of the two-sided 95% CI for major adverse CV events (MACE) of less than 1.80 preapproval and 1.30 postapproval. Over 25 large, prospective, randomized, controlled clinical trials involving nearly 195,000 subjects thus far have been completed or are ongoing in accordance with this guidance. The results of seven trials have been presented so far—three with dipeptidyl peptidase 4 inhibitors, one with a sodium–glucose cotransporter 2 (SGLT2) inhibitor, and three with glucagon-like peptide 1 receptor agonists (GLP-1 RA). While all seven trials showed noninferiority in the rate of MACE with the use of these agents compared with placebo, three of them revealed CV benefits. Treatment with empagliflozin (an SGLT2 inhibitor) and treatment with liraglutide (a GLP-1 RA) both significantly reduced the risk of MACE, mortality from CV causes, and mortality from any cause when compared with placebo. Treatment with semaglutide, another GLP-1 RA, showed a significantly lower rate of MACE but not mortality from CV or any cause compared with placebo. In all of the trials, the effects of treatment on outcomes were out of proportion to the small differences in glycemic control levels, suggesting that the effects observed were likely unrelated to differences in the glucose-lowering efficacy. Overall, the results of these trials yield a favorable benefit-risk balance for these therapies in mitigating CV risk in patients with type 2 diabetes. More research is needed to elucidate the underlying mechanisms and confirm whether the CV benefits are a class effect or whether the benefits persist in patients without established CV disease or are evident even in patients without diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the hsCRP reduction observed with the GLP-1RA semaglutide suggests that it might exert anti-inflammatory effects.”
From Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials (2022) · cites this paper as [38]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 1×
“Primarily in response to the findings of possible increased CV risk with rosiglitazone (2), the U.”
BackgroundMultifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129 · cited 7×
“Thus, there are legitimate arguments for including silent MIs in the overall adjudication ofMIs in CV outcome trials.”
MethodInfluentialEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035
CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
Toward Evidence-Based Medical Statistics. 2: The Bayes Factor
Goodman, S. N. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-12-199906150-00019 · Cited by 912
Fitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv728 · Cited by 907
Margulies, K. B., Hernandez, A. F., Redfield, M. M., Givertz, M. M., Oliveira, G. H., Cole, R., Mann, D. L., Whellan, D. J., Kiernan, M. S., Felker, G. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.10260 · Cited by 706
Jorsal, A., Kistorp, C., Holmager, P., Tougaard, R. S., Nielsen, R., Hänselmann, A., Nilsson, B., Møller, J. E., Hjort, J., Rasmussen, J., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.657 · Cited by 592
Cardiovascular Actions of Incretin-Based Therapies
Ussher, J. R., & Drucker, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.301958 · Cited by 358 · cited 2×
“In addition to glycemic control andweight loss, GLP-1 RA improve other possible risk factors including blood pressure, inflammatory markers, insulin sensitivity, and lipid profile and delay the progression of atherosclerotic disease (24).”
BackgroundHeart Rate as a Risk Factor for Cardiovascular Disease
Perret-Guillaume, C., Joly, L., & Benetos, A. (2009) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2009.05.003 · Cited by 222 · cited 1×
“increased CV morbidity and mortality, however, this relationship might be confounded (15).”
BackgroundZhang, Z.-M., Rautaharju, P. M., Prineas, R. J., Rodriguez, C. J., Loehr, L., Rosamond, W. D., Kitzman, D., Couper, D., & Soliman, E. Z. (2016) · Circulation · doi:10.1161/circulationaha.115.021177 · Cited by 211
Rodríguez-Gutiérrez, R., & Montori, V. M. (2016) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.116.002901 · Cited by 176 · cited 2×
“Questions have also been raised regarding whether intensive glucose control in type 2 diabetes yields unequivocal evidenceof benefit onhardmicrovascular complications, such as vision loss or renal failure (35).”
BackgroundMethodHerman, W. H., Petersen, M., & Kalyani, R. R. (2017) · Diabetes Care · doi:10.2337/dci17-0007 · Cited by 124
Burgess, D. C., Hunt, D., Li, L., Zannino, D., Williamson, E., Davis, T. M. E., Laakso, M., Kesaniemi, Y. A., Zhang, J., Sy, R. W., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp377 · Cited by 119 · cited 7×
“Thus, there are legitimate arguments for including silent MIs in the overall adjudication ofMIs in CV outcome trials.”
BackgroundMethodInfluentialMarso, S. P., Lindsey, J. B., Stolker, J. M., House, J. A., Martinez Ravn, G., Kennedy, K. F., Jensen, T. M., & Buse, J. B. (2011) · Diabetes and Vascular Disease Research · doi:10.1177/1479164111408937 · Cited by 103
Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
Smith, R. J., Goldfine, A. B., & Hiatt, W. R. (2016) · Diabetes Care · doi:10.2337/dc15-2237 · Cited by 60 · cited 1×
“far calls into question the wisdom of a default approach that assumes all antidiabetes drugs are suspected of CV harm unless proven otherwise (36).”
BackgroundShurter, A., Genter, P., Ouyang, D., & Ipp, E. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.03.018 · Cited by 57 · cited 1×
“to rapid glucose lowering on progression of diabetic retinopathy as has been previously described (18).”
BackgroundKumarathurai, P., Anholm, C., Nielsen, O. W., Kristiansen, O. P., Mølvig, J., Madsbad, S., Haugaard, S. B., & Sajadieh, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0425-2 · Cited by 54 · cited 1×
“tes and coronary artery disease (25), on”
Is the Mortality Benefit With Empagliflozin in Type 2 Diabetes Mellitus Too Good To Be True?
Kaul, S. (2016) · Circulation · doi:10.1161/circulationaha.116.022537 · Cited by 27 · cited 4×
“In contrast, CV death reduction was based on a large number of events (309 in EMPA-REG OUTCOME and 497 in LEADER), was clinically important, and was statistically robust, yielding overwhelming evidence of benefit that does not require confirmation (14).”
BackgroundMethodInfluentialSelf-citation
Research works printed but not linked: 1
- Committee for Medicinal Products for Human Use, 2012, Guideline on Clinical Investigation of Medicinal Products in the Treatment or Prevention of Diabetes Mellitus
Cited by
Rakipovski, G., Rolin, B., Nøhr, J., Klewe, I., Frederiksen, K. S., Augustin, R., Hecksher-Sørensen, J., Ingvorsen, C., Polex-Wolf, J., & Knudsen, L. B. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.09.004 · Cited by 509
“The CV risk reduction (RR) observed using the GLP1RAs liraglutide and semaglutide in the LEADER and SUSTAIN-6 trials is proposed to be mediated through antiatherosclerotic mechanisms (6,7,9).”
MethodDiscovery, characterization, and clinical development of the glucagon-like peptides
Drucker, D. J., Habener, J. F., & Holst, J. J. (2017) · Journal of Clinical Investigation · doi:10.1172/jci97233 · Cited by 418
“…questions about the potential clinical classes used for treatment of T2D, the GLP-1R agonists and SGLT-2 inhibitors, produce weight loss, effective reduction of A1c, a low incidence of hypoglycemia, and reductions in rates of major adverse cardiovascular events and cardiovascular death (75, 87).”
BackgroundDedov, I. I., Shestakova, M. V., Vikulova, O. K., Zheleznyakova, A. V., Isakov, M. A., Sazonova, D. V., & Mokrysheva, N. G. (2023) · Diabetes mellitus · doi:10.14341/dm13035 · Cited by 281
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Vikulova, O. K., Galstyan, G. R., Kuraeva, T. L., Peterkova, V. A., Smirnova, O. M., Starostina, E. G., Surkova, E. V., et al. (2019) · Diabetes mellitus · doi:10.14341/dm221s1 · Cited by 257
Dedov, I., Shestakova, M., Mayorov, A., Mokrysheva, N., Andreeva, E., Bezlepkina, O., Peterkova, V., Artemova, E., Bardiugov, P., Beshlieva, D., et al. (2023) · Diabetes mellitus · doi:10.14341/dm13042 · Cited by 214
Metadata
- Authors
- Kaul, S.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Corresponding author
- Kaul, Sanjay
- ORCID
- Kaul, Sanjay
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-06-13
- Volume
- 40
- Issue
- 7
- Pages
- 821-831
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2711994541
- Cited by
- 62
- References
- 29
- Citations by year
- 2026: 2 · 2025: 4 · 2023: 2 · 2022: 5 · 2021: 6 · 2020: 8 · 2019: 11 · 2018: 18 · 2017: 6
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Update notices
- correction (2018-03-01)
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- type 2 diabetes, cardiovascular risk, major adverse cardiovascular events, empagliflozin, liraglutide, semaglutide, SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, EMPA-REG OUTCOME, LEADER trial, SUSTAIN 6 trial, benefit-risk balance, cardiovascular mortality
- MeSH terms
- Liraglutide, Semaglutide, Animals, Benzhydryl Compounds, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Glucosides, Humans, Hypoglycemic Agents, Risk Factors, Randomized Controlled Trials as Topic, Treatment Outcome, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.